ABSTRACT
We examined the effects of insulin on fatty acid uptake in L-cell fibroblasts, using cis-parinaric acid to measure uptake rates in the absence of esterification and [3H]oleic acid to measure uptake rates in the presence of esterification. L-cells exhibited both high and low affinity insulin binding sites with Kd of 23 nM and 220 nM and a cellular density of 1.4 and 6.8 x 10(5) sites/cell, respectively. Insulin in the range 10(-9) to 10(-7) M significantly decreased both the initial rate and maximal extent of cis-parinaric acid uptake by 24 to 30%. Insulin also reduced [3H]oleic acid uptake up to 35%, depending on insulin concentration and decreased the amount of fatty acid esterified into the phospholipids and neutral lipids by 28 and 70%, respectively. In contrast, glucagon or epinephrine stimulated both the initial rate and extent of cis-parinaric acid uptake 18 and 25%, respectively. Because L-cells lack P-adrenergic receptors, the epinephrine effect was not the result of P-receptor stimulation. Hence, insulin altered not only fatty acid uptake, as determined by cis-parinaric and oleic acid uptake, but also altered the intracellular oleic acid esterification.
Subject(s)
Fatty Acids/metabolism , Fibroblasts/metabolism , Insulin/pharmacology , Adenylyl Cyclases/metabolism , Animals , Biological Transport/drug effects , Esters/metabolism , Fatty Acids, Unsaturated/metabolism , L Cells/metabolism , Mice , Oleic Acid/metabolism , Receptor, Insulin/metabolism , Receptors, Adrenergic, beta/metabolismABSTRACT
To elucidate the regulatory pathway through which pancreastatin inhibits insulin secretion, RINm5F insulinoma cells were challenged with physiological and pharmacological probes known to stimulate insulin release through different mechanisms. Utilizing the electrophysiological technique of capacitance measurements as a correlate to exocytosis, pancreastatin was found to significantly diminish maximum capacitance changes evoked by glyceraldehyde, an effect which was attenuated in pertussis toxin-treated cells. In static incubations of this cell line, pancreastatin significantly inhibited insulin secretion stimulated by glyceraldehyde, carbachol and A23187, secretagogues known to directly elevate beta-cell cytosolic Ca2+. This peptide also inhibited insulin secretion stimulated by phorbol myristate acetate (PMA), but only at incubation times < or = 15 min. It was without effect on insulin secretion stimulated by mastoparan and longer incubations (30 min) with PMA, where the secretory mechanisms are not necessarily Ca(2+)-dependent. Additionally, pancreastatin had no effect on carbachol-generated inositol phosphate accumulation but inhibited simultaneously stimulated insulin secretion. All inhibitory effects of pancreastatin were pertussis toxin sensitive. These results suggest that pancreastatin inhibits insulin secretion in RINm5F cells through a G-protein regulated mechanism at a control point involved in the Ca(2+)-directed exocytotic machinery, a feature shared by other physiologic inhibitors of insulin secretion.
Subject(s)
Calcium/metabolism , Exocytosis/physiology , Insulin/metabolism , Insulinoma/metabolism , Pancreatic Hormones/pharmacology , Pancreatic Neoplasms/metabolism , Animals , Anti-Bacterial Agents/pharmacology , Calcimycin/pharmacology , Carbachol/pharmacology , Chromogranin A , Exocytosis/drug effects , GTP-Binding Proteins/metabolism , Glyceraldehyde/pharmacology , Inositol Phosphates/metabolism , Insulin Secretion , Insulinoma/drug therapy , Insulinoma/pathology , Intercellular Signaling Peptides and Proteins , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/pathology , Peptides , Pertussis Toxin , Phorbol Esters/pharmacology , Rats , Tumor Cells, Cultured , Virulence Factors, Bordetella/pharmacology , Wasp Venoms/pharmacologyABSTRACT
Aspartame is an artificial sweetener completely metabolized in the gut and absorbed as aspartate, phenylalanine, and methanol. Phenylalanine is thought to mediate or exacerbate hepatic encephalopathy, and an impaired liver may not be able to cope with the ammoniagenic properties of the amino acid constituents, or adequately metabolize methanol. Thus, we compared the clinical and biochemical effects of a single ingestion of aspartame (15 mg/kg) to skim milk (phenylalanine content equimolar to aspartame) and placebo in patients with chronic, alcoholic liver disease in a randomized, crossover study. Aspartame produced an elevation of plasma phenylalanine significantly greater than milk and placebo (Cmax 14.55 +/- 7.38, 10.95 +/- 4.95, 8.84 +/- 4.55 mumol/dl, respectively; p < 0.01). However, quantified encephalopathic changes were observed only with milk (p < 0.05). Plasma aspartate, methanol, formate, and ammonia levels remained unchanged after all treatments. The lack of clinical derangements in encephalopathic indices, methanol accumulation, or biochemical changes in liver status suggests that a single large dose of aspartame (representing 5 times the average daily intake of adults) may be used safely by patients with chronic, stable liver disease.
Subject(s)
Aspartame/pharmacology , Liver Diseases, Alcoholic/metabolism , Liver/metabolism , Phenylalanine/metabolism , Amino Acids/blood , Animals , Aspartame/toxicity , Drug Evaluation , Hepatic Encephalopathy/chemically induced , Humans , Male , Methanol/blood , Middle Aged , Milk , Risk FactorsABSTRACT
The effects of left cervical vagus nerve stimulation on glucagon secretion were studied in streptozotocin-diabetic and age-matched control adult male rats. At two-week intervals, after the induction of streptozotocin-diabetes, streptozotocin-diabetic and age-matched control rats were anesthetized with chloral hydrate (350 mg/kg, ip). Left cervical vagus nerves were electrically stimulated via a Grass stimulator with 5-volt monophasic pulses of 3 msec duration at a frequency of 20 Hz for 1, 2, and 4 min. Arginine-induced glucagon secretion was also determined. Vagus nerve-stimulated (2 and 4 min) glucagon secretion deteriorated as the duration of streptozotocin-diabetes increased. Glucagon secretion in response to vagus nerve stimulation was virtually absent by 12 weeks of streptozotocin-diabetes. However, arginine-induced glucagon secretion was unaffected. Subsequent experiments showed that the defect in glucagon secretion from vagal stimulation occurred concurrently with that seen from insulin-induced hypoglycemia. These results indicate that the impaired hypoglycemia-induced glucagon secretion in long-term streptozotocin-diabetic rats may be correlated with the deterioration of the parasympathetic nervous system transmission in streptozotocin-diabetes.